Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Crucell Announces PER.C6® Licensing Agreement with Vascular Biogenics

05 Apr 2005 - Crucell N.V. announced that it has signed a PER.C6® research license agreement with Israeli biopharmaceutical company Vascular Biogenics Ltd. The non-exclusive agreement allows Vascular Biogenics to use the PER.C6® cell line for the preparation and evaluation of gene therapeutics based on adenoviral vectors.
 
Under the terms of the agreement, Vascular Biogenics will make a research license payment and annual maintenance fees. Further financial details were not disclosed.